TO THE EDITOR
All-trans retinoic acid (ATRA), Am80 and arsenic trioxide (As 2 O 3 ) have marked a great advance in the management of patients with acute promyelocytic leukemia (APL). Among them, arsenic trioxide (As 2 O 3 ) has marked a great advance in the management of patients with APL. 1 However, cardiac toxicities related to As 2 O 3 have been reported in patients with relapsed/ refractory APL. 2 Electrocardiographic abnormalities, such as QRS complex broadening, prolonged QT intervals, ST-segment depression, T-wave flattening, arrhythmia and atrioventricular block, have been reported in acute arsenic poisoning.
2, 3 We previously reported that certain adverse cardiac effects are associated with the use of As 2 O 3 treatment for APL. 2 Prolonged QTc, ventricular premature contractions (VPCs) and ventricular tachycardia (VT) were observed during As 2 O 3 treatment by a wireless monitoring and a 12-lead electrocardiography. However, the mechanism of these abnormalities has not been elucidated. Most of relapse/refractory APL patients receiving As 2 O 3 have been heavily treated with chemotherapeutic agents including anthracyclines. Therefore, cardiac toxicity may become more pronounced under As 2 O 3 treatment. However, there are not enough techniques to select patients at risk of lifethreatening cardiac toxicity.
The 24-h ambulatory heart rate analysis has revealed that decreased heart rate variability (HRV) is associated with an increased risk of mortality and susceptibility to life-threatening arrhythmias in patients with coronary disease. 4 HRV has been one of the valuable methods to assess the mechanism of cardiac damages. Impairment of HRV, which was related to the abnormality in autonomic regulation, has also been reported in patients treated with chemotherapies including anthracyclines, vinca alkaloids and paclitaxel. 5 We monitored 24-h ambulatory electrocardiograms (ECGs) during and after As 2 O 3 treatment in six patients with APL, and tried to clarify the mechanism of cardiac toxicity.
We used As 2 O 3 to treat six patients with APL who relapsed after extensive previous therapy with ATRA and chemotherapies. As 2 O 3 was kindly provided from Cell Therapeutics (Seattle, WA, USA). The drug was administered at a dose of 0.15 mg/kg given daily for a cumulative maximum of 60 days (25-60 days), being diluted in 500 ml of 5% dextrose and administered intravenously over 2 h. All patients stayed in our hospital during this study, and achieved complete remission again without using other chemotherapeutic agents.
At 3 weeks after the start of As 2 O 3 treatment, 24-h ambulatory ECGs were recorded and 1 week after the end of the treatment.
Before obtaining informed consent, patients with severe symptoms such as fever, fatigue, appetite loss and tendency to severe bleeding were excluded from this study for ethical reasons. We did not analyze it before As 2 O 3 treatment because the treatment for leukemia should be started as soon as possible under its acute clinical course. And, the bleeding tendency in the skin often prevented the study before As 2 O 3 treatment. General symptoms, hospital life level, mean blood pressure, heart rate, hemoglobin levels and cardiothoracic rates were not significantly changed at the two time points analyzed. The time series of normal RR intervals for 24 h was analyzed with a fast Fourier transform algorithm; and the low-frequency (LF; 0.04-0.15 Hz) power, high-frequency (HF; 0.15-0.40 Hz) power, total power (TP) and normalized LF (LF/TP) were computed using a Marquette HRV program (Milwaukee, WI, USA). LF power relates to baroreflex capacity and is under the control of sympathetic and parasympathetic system. HF power relates to vagus reflex and reflects respiratory cardiac rhythm variation.
Prolonged QTc was observed during As 2 O 3 treatment in all cases (P ¼ 0.04). PVCs and supraventricular premature contractions (SPVCs) increased considerably in two cases. VT and torsade de pointes were not observed during the analysis of 24-h ambulatory ECG. Runs of SVPCs also increased during As 2 O 3 Figure 1 . We also calculated four time-domain measures. The 24-h standard deviation (s.d.) of the averages of NN intervals (SDANN), which is considered as a component of LF, decreased except in one patient (P ¼ 0.043). The square root of the mean of the sum of the squares of differences between adjacent NN intervals (rMSSD) and the percentage of differences between adjacent normal NN intervals 450 m (pNN50), which are the closely related components of HF, decreased significantly during As 2 O 3 treatment in all patients (P ¼ 0.042 and 0.024, respectively).
Cardiac adverse effects on As 2 O 3 treatment have been reported despite the excellent results on APL.
2,3 On the background, many patients with APL have been heavily treated with chemotherapy and ATRA, and the cardiac damages could exist in the face of As 2 O 3 treatment. Therefore, the toxicity can easily appear in As 2 O 3 treatment.
We previously reported prolongation of the QT interval and VT as adverse effects of As 2 O 3 treatment. 2 However, it remains unclear why tachyarrythmias such as sustained VT or torsade de pointes occur and why As 2 O 3 prolongs the QT interval. Chiang et al 6 analyzed the action potential and QT interval in guineapig papillary muscle. They reported that As 2 O 3 dose-dependently prolonged the action potential duration and QT interval. As 2 O 3 might directly delay cardiac repolarization, and it could explain the occurrence of torsade de pointes in susceptible patients. They suspected that As 2 O 3 might block the rapid component of the delayed rectifier K þ channel. On the other hand, metals are known to affect the peripheral nervous system diffusely, and the imbalance of the autonomic nervous system may be involved in the genesis of arrythmias. 7 In addition, As 2 O 3 also causes widespread damage in many organs by combining with sulfhydryl proteins. In this study, proliferation of VPC, SVPC, prolonged QT interval and VT occurred in some cases. On the other hand, cardiac autonomic nervous system has been often analyzed with HRV. We found impairment of HRV, which has been often analyzed for cardiac autonomic nervous system. Impairment of HRV has been reported during and after the chemotherapy for patients with cancer. 5 HF and LF components have been considered as the most important indices of HRV. 4 The vagal activity is a major contributor of HF component, and both sympathetic and vagal effects relate to LF component. Atropine and vagotomy reduce both LF and HF. 4 In this study, both LF and HF decreased significantly during As 2 O 3 treatment and improved after it. Anticholinergic effect of arsenic acid has been reported within the central and peripheral nervous system. 8 In these reports, arsenite inhibits the release and the synthesis of acetylcholine. The same anticholinergic effect might occur in autonomic cardiac regulation.
Our results suggest that As 2 O 3 might affect QT prolongation and arrhythmia via impairment of autonomic cardiac regulation. The analysis of HRV might be one of the effective methods to estimate the mortality and the mechanism of the cardiac toxicity of As 2 O 3 treatment. Additional investigation in excitationcontraction coupling and cardiac contractile might clarify the further mechanism of cardiac toxicity of As 2 O 3 . On the other hand, As 2 O 3 treatment seems to be a good model to investigate the relationships between them. School of Medicine, Nagoya, Japan; 2 Laboratory Medicine, Hamamatsu University School of Medicine, Nagoya, Japan;
